Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent μ-/δ-opioid receptor antagonist, regulates obese-related factors in mice

European Journal of Pharmacology

Volumn 616, Issue 1-3, 2009, Pages 115-121

  Marczak, Ewa D ^a   Jinsmaa, Yunden ^a   Myers, Page H ^a   Blankenship, Terry ^a   Wilson, Ralph ^a   Balboni, Gianfranco ^b   Salvadori, Severo ^c   Lazarus, Lawrence H ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

(ob ob mouse); Bone mineral density; Dmt Tic pharmacophore; Dual opioid receptor antagonist; Glucose; Insulin; Obesity

Indexed keywords

CHOLESTEROL; DELTA OPIATE RECEPTOR ANTAGONIST; GLUCOSE; INSULIN; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; MZ 2; NALTREXONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; EXERCISE; FAT CONTENT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; MOUSE; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; BONE DENSITY; CELL LINE; CELL PROLIFERATION; EATING; FEMALE; HUMANS; INSULIN; MICE; MINERALS; OBESITY; OLIGOPEPTIDES; OSTEOBLASTS; PHYSICAL CONDITIONING, ANIMAL; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; SODIUM CHLORIDE;

EID: 67651125092     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.041     Document Type: Article

References (46)

1. Achten J., and Jeukendrup A.E. Optimizing fat oxidation through exercise and diet. Nutrition 20 (2004) 716-727 (Burbank, Los Angeles County, Calif)
2. Atkinson R.L. Opioid regulation of food intake and body weight in humans. Fed. Proc. 46 (1987) 178-182
3. Avena N.M., Rada P., and Hoebel B.G. Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake. Neurosci. Biobehav. Rev. 32 (2008) 20-39
4. Balboni G., Onnis V., Congiu C., Zotti M., Sasaki Y., Ambo A., Bryant S.D., Jinsmaa Y., Lazarus L.H., Trapella C., and Salvadori S. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J. Med. Chem. 49 (2006) 5610-5617
5. Berestov L.A. Endogenous morphines-possible role in the pathogenesis of exogenous-constitutional obesity. Ter Arkh. 55 (1983) 131-134
6. Carey M.P., Ross J.A., and Enns M.P. Naloxone suppresses feeding and drinking but not wheel running in rats. Pharmacol. Biochem. Behav. 14 (1981) 569-571
7. Cole J.L., Berman N., and Bodnar R.J. Evaluation of chronic opioid receptor antagonist effects upon weight and intake measures in lean and obese Zucker rats. Peptides 18 (1997) 1201-1207
8. Cota D., Tschop M.H., Horvath T.L., and Levine A.S. Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. Brain Res. Brain Res. Rev. 51 (2006) 85-107
9. Daniell H.W. Hypogonadism in men consuming sustained-action oral opioids. J. Pain 3 (2002) 377-384
10. Elhassan A.M., Lindgren J.U., Hultenby K., Bergstrom J., and Adem A. Methionine-enkephalin in bone and joint tissues. J. Bone Miner. Res. 13 (1998) 88-95
11. Ensrud K.E., Blackwell T., Mangione C.M., Bowman P.J., Bauer D.C., Schwartz A., Hanlon J.T., Nevitt M.C., and Whooley M.A. Central nervous system active medications and risk for fractures in older women. Arch. Intern. Med. 163 (2003) 949-957
12. Fields H.L. Understanding how opioids contribute to reward and analgesia. Reg. Anesth. Pain Med. 32 (2007) 242-246
13. Gellner, R., Domschke, W., 2008. [Epidemiology of obesity]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 79, 807-810, 812-806, 818.
14. Gregory C.A., Gunn W.G., Peister A., and Prockop D.J. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal. Biochem. 329 (2004) 77-84
15. Hagihara Y., Fukuda S., Goto S., Iida H., Yamazaki M., and Moriya H. How many days per week should rats undergo running exercise to increase BMD?. J. Bone Miner. Metab. 23 (2005) 289-294
16. Han W., Hata H., Imbe H., Liu Q.R., Takamatsu Y., Koizumi M., Murphy N.P., Senba E., Uhl G.R., Sora I., and Ikeda K. Increased body weight in mice lacking mu-opioid receptors. NeuroReport 17 (2006) 941-944
17. Jarosz P.A., and Metzger B.L. The effect of opioid antagonism on food intake behavior and body weight in a biobehavioral model of obese binge eating. Biol. Res. Nurs. 3 (2002) 198-209
18. Jinsmaa Y., Marczak E.D., Balboni G., Salvadori S., and Lazarus L.H. Inhibition of the development of morphine tolerance by a potent dual mu-/delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH(2)-Ph. Pharmacol. Biochem. Behav. 90 (2008) 651-657
19. Jurimae T., Viru A., Karelson K., and Smirnova T. Biochemical changes in blood during the long and short triathlon competition. J. Sports Med. Phys. Fitness 29 (1989) 305-309
20. Kas M.J., van den Bos R., Baars A.M., Lubbers M., Lesscher H.M., Hillebrand J.J., Schuller A.G., Pintar J.E., and Spruijt B.M. Mu-opioid receptor knockout mice show diminished food-anticipatory activity. Eur. J. Neurosci. 20 (2004) 1624-1632
21. Khawaja X.Z., Bailey C.J., and Green I.C. Central mu, delta, and kappa opioid binding sites, and brain and pituitary beta-endorphin and met-enkephalin in genetically obese (ob/ob) and lean mice. Life Sci. 44 (1989) 1097-1105
22. Knechtle B. Exercise intensity and fat burning-theoretical principles and practical considerations. Praxis 91 (2002) 915-919
23. Levine A.S., Grace M., Billington C.J., and Zimmerman D.M. Central administration of the opioid antagonist, LY255582, decreases short- and long-term food intake in rats. Brain Res. 566 (1991) 193-197
24. 2+ in the mouse; some parameters of the chemical reaction in vitro. Acta Anat. (Basel) 114 (1982) 268-280
25. Liskov A.V., Solnyshkova T.G., Frolov B.A., and Pavlovichev S.A. Effect of naloxone hydrochloride on osteogenesis in chick embryos. Bull. Exp. Biol. Med. 139 (2005) 331-333
26. 1]-endomorphins are micro-opioid receptor antagonists lacking inverse agonist properties. J. Pharmacol. Exp. Ther. 323 (2007) 374-380
27. McCormack J.F., and Denbow D.M. Ingestive responses to mu and delta opioid receptor agonists in the domestic fowl. Br. Poult. Sci. 30 (1989) 327-340
28. Nakayama G.R., Caton M.C., Nova M.P., and Parandoosh Z. Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J. Immunol. Methods 204 (1997) 205-208
29. Newhall K.M., Rodnick K.J., van der Meulen M.C., Carter D.R., and Marcus R. Effects of voluntary exercise on bone mineral content in rats. J. Bone Miner. Res. 6 (1991) 289-296
30. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
31. Papaleo F., Kieffer B.L., Tabarin A., and Contarino A. Decreased motivation to eat in mu-opioid receptor-deficient mice. Eur. J. Neurosci. 25 (2007) 3398-3405
32. Peng X., Knapp B.I., Bidlack J.M., and Neumeyer J.L. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J. Med. Chem. 50 (2007) 2254-2258
33. Perez-Castrillon J.L., Olmos J.M., Gomez J.J., Barrallo A., Riancho J.A., Perera L., Valero C., Amado J.A., and Gonzalez-Macias J. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 72 (2000) 187-194
34. Pietrobelli A., Wang Z., Formica C., and Heymsfield S.B. Dual-energy X-ray absorptiometry: fat estimation errors due to variation in soft tissue hydration. Am. J. Physiol. 274 (1998) E808-E816
35. Recant L., Voyles N.R., Luciano M., and Pert C.B. Naltrexone reduces weight gain, alters "beta-endorphin", and reduces insulin output from pancreatic islets of genetically obese mice. Peptides 1 (1980) 309-313
36. Shaw W.N., Mitch C.H., Leander J.D., Mendelsohn L.G., and Zimmerman D.M. The effect of the opioid antagonist LY255582 on body weight of the obese Zucker rat. Int. J. Obes. 15 (1991) 387-395
37. Shorr R.I., Griffin M.R., Daugherty J.R., and Ray W.A. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J. Gerontol. 47 (1992) M111-M115
38. Sisti H.M., and Lewis M.J. Naloxone suppression and morphine enhancement of voluntary wheel-running activity in rats. Pharmacol. Biochem. Behav. 70 (2001) 359-365
39. Tabarin A., Diz-Chaves Y., Carmona Mdel C., Catargi B., Zorrilla E.P., Roberts A.J., Coscina D.V., Rousset S., Redonnet A., Parker G.C., Inoue K., Ricquier D., Penicaud L., Kieffer B.L., and Koob G.F. Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a "thrifty gene". Diabetes 54 (2005) 3510-3516
40. Ukai M., and Kameyama T. Multi-dimensional analyses of behavior in mice treated with naltrexone. Physiol. Behav. 34 (1985) 311-313
41. Ukai M., and Kameyama T. Naloxone specifically blocks the linear locomotion in mice. Brain Res. 328 (1985) 378-380
42. Vestergaard P., Rejnmark L., and Mosekilde L. Fracture risk associated with the use of morphine and opiates. J. Intern. Med. 260 (2006) 76-87
43. Wang G.J., Volkow N.D., Thanos P.K., and Fowler J.S. Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. J. Addict. Dis. 23 (2004) 39-53
44. Wang G.J., Yang J., Volkow N.D., Telang F., Ma Y., Zhu W., Wong C.T., Tomasi D., Thanos P.K., and Fowler J.S. Gastric stimulation in obese subjects activates the hippocampus and other regions involved in brain reward circuitry. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15641-15645
45. Yeomans M.R., and Gray R.W. Opioid peptides and the control of human ingestive behaviour. Neurosci. Biobehav. Rev. 26 (2002) 713-728
46. Zhang J., Frassetto A., Huang R.R., Lao J.Z., Pasternak A., Wang S.P., Metzger J.M., Strack A.M., Fong T.M., and Chen R.Z. The mu-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist. Eur. J. Pharmacol. 545 (2006) 147-152